JANX
Janux Therapeutics, Inc.
Biotechnology · Healthcare · United States
16.00
close · 2026-08-13
value
78
cheaper than peers78
quality
62
stronger fundamentals62
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.01× | 96 |
| EV to EBITDA | 0.13× | 96 |
| price to sales | 66.43× | 21 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.3% | 86 |
| return on equity | -11.7% | 69 |
| operating margin | -916.5% | 16 |
3 of 4 measures available
Facts
| market cap | $978M |
| free cash flow | -$54.0M |
| employees | 108 |
| first trade | 2021-06-11 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |